Amlodipine/valsartan - Novartis
Alternative Names: Amlodipine 10mg/Valsartan 160mg; Amlodipine besilate/valsartan; Amlodipine besylate/valsartan; Dafiro; Exforge; EXPO-G-Tab; ID1803; VAA489; Valsartan/amlodipineLatest Information Update: 06 Dec 2019
Price :
$50 *
At a glance
- Originator Novartis
- Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Ischaemic heart disorder therapies; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 04 Dec 2019 IlDong Pharmaceutical plans a phase I pharmacodynamics/pharmacokinetic interaction and safety study in Healthy volunteers (ID-VARE-101; NCT04185090)
- 28 Aug 2019 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO, Tablet)
- 22 May 2019 Kyung Dong Pharmaceutical completes the phase I KD5001 trial in Hypertension (In volunteers) in South Korea (PO) (KCT0001660)